Zonova develops novel antimicrobial technology for integration into medical devices. This technology enhances device functionality by actively combating microbial colonization. The primary value is reducing the clinical reliance on systemic antibiotics.
Funding
Funding not disclosed
Founders
Product
Problem
Medical devices are susceptible to microbial colonization, which can lead to device-associated infections and increased reliance on antibiotics. This poses a significant challenge for infection control in healthcare settings and impacts patient outcomes.
Solution
Zonova develops and integrates novel antimicrobial surface technology into medical devices to prevent microbial adhesion and biofilm formation. This proprietary technology creates a non-leaching, durable barrier that significantly reduces the risk of device-related infections. By inhibiting bacterial colonization at the material interface, Zonova's solution offers a proactive approach to infection prevention, thereby decreasing the need for systemic antibiotic treatments and improving patient safety. The technology is designed for seamless integration into existing manufacturing processes for a wide range of medical device types.
Target Audience
Zonova targets medical device manufacturers seeking to enhance the infection control properties of their products and healthcare systems aiming to reduce device-related infections.
Features
- Antimicrobial surface technology that prevents microbial colonization and biofilm formation.
- Non-leaching, durable surface treatment for long-term efficacy.
- Designed for integration into various medical device manufacturing workflows.
- Reduces the risk of device-associated infections without the use of antibiotics.
- Proprietary material science approach to surface modification.